Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / VTGN - Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou

VTGN - Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou

VistaGen Therapeutics Inc.
  • VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou.
  • Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
  • Shanghai Junshi Bio was granted US Orphan Drug Designation for toripalimab, its PD-1 inhibitor, to treat small cell lung cancer.

For further details see:

Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou
Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...